CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188300 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Himanshu Dhanda und 12 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-Centre for Cancer Pathology, New Delhi 110029, India. Hauptthemen laut MEDLINE: Signal Transduction, Glycogen Synthase Kinase 3, Cyclic AMP Response Element-Binding Protein, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL), driven by the BCR-ABL1 fusion, remains highly aggressive, with poor prognosis despite tyrosine kinase inhibitor (TKI) therapy. Aberrant PI3K/Akt/mTOR pathway activation contributes to resistance, warranting identification of predictive kinase biomarkers. To identify and validate critical phospho-kinase markers within the PI3K/Akt/mTOR axis as candidate adaptive signaling nodes and exploratory prognostic markers in Ph+ B-ALL. Network pharmacology using STRING and Cytoscape mapped the protein–protein interactions, identifying high-centrality nodes. Functional enrichment analyses (GO/KEGG) were then performed via ShinyGO. Experimentally, phospho-kinase arrays profiled 39 kinase phosphorylation sites in Ph+ B-ALL cells (SUPB-15) treated with PI3K/Akt/mTOR inhibitors (Rapamycin, GDC-0941, GSK690693, Perifosine). Gene expression was validated by RT-qPCR in 100 Ph+ B-ALL patients and protein validation employed Western blot in 50 patient samples with 15 and five healthy controls, respectively. Network analysis identified CREB1 and GSK3 isoforms as central hub regulators. Phospho-kinase profiling revealed p-CREB (Ser133) phosphorylation upregulation following Perifosine, GDC-0941, and Rapamycin treatment, with no statistically significant change after GSK690693. p-GSK3α/β (Ser21/9) phosphorylation showed a statistically significant increase after Perifosine, with non-significant trends after GDC-0941, and a significant reduction following Rapamycin. Hierarchical clustering then divided proteins into four distinct clusters positioning CREB1 in cluster 3 and GSK3α/β in cluster 2 as candidate adaptive response markers based on their phosphorylation profiles. RT-qPCR demonstrated marked downregulation of GSK3α (approximately 71%), GSK3β (63%), and CREB1 (65%) transcripts in patients versus controls, with even greater suppression seen in cell lines. Conversely, Western blot revealed a significant 2.49 fold elevated p-CREB (Ser133) (β = 1.317, p = 0.000347) and a phospho-GSK3α/β (Ser21/9) level that did not differ significantly between patients and controls (β = 0.467, p = 0.466), revealing mRNA–protein discordance indicative of compensatory post-transcriptional and post-translational regulation. These findings represent treatment-associated and disease-state associations between altered phosphorylation states and the Ph+ B-ALL context; functional validation remains an essential next step. mRNA–protein discordance with transcriptional downregulation (63–71%) contrasting with elevated p-CREB levels (2.49-fold, p = 0.000347) suggests post-translational compensatory mechanisms under therapeutic pressure. CREB1 and GSK3 isoforms emerge as central network nodes that might potentially mediate adaptive resistance, although functional validation is required. It should be noted that the evidence presented is associative rather than causal and a direct link between the observed phosphorylation changes and clinical drug resistance has not been established in this study. Sustained CREB phosphorylation despite PI3K/Akt/mTOR inhibition implicates alternative kinase pathways (MAPK/ERK, CaMK), supporting rational combination therapy strategies. These findings position p-CREB and p-GSK-3α/β as candidate biomarkers, highlighting the value of phospho-proteomics over transcriptomics alone in capturing pathway activation. Multi-omics integration may prove essential for overcoming adaptive resistance in ALL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICMR-Centre for Cancer Pathology, New Delhi 110029, India.
- Manipal Academy of Higher Education, Manipal 576104, India.
- ICMR-National Institute of Child Health Research, New Delhi 110029, India.
- Dr. B.R.A. Institute of Rotary Cancer Hospital, All India Institute of Medical Science, New Delhi 110029, India.
- Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi 110029, India.
ORCID-Profile: Himanshu Dhanda, Bhavika Rishi, Pranay Tanwar, Sufian Zaheer, Amitabh Singh, Sumita Chaudhry, Fouzia Siraj, Aroonima Misra
Förderung
- Indian Council of Medical Research
Zitieren
APA
Dhanda, H., Zaman, S., Swain, S. K., Kushwaha, N., Kamal, R., Kaur, M., Rishi, B., Tanwar, P., Zaheer, S., Singh, A., Chaudhry, S., Siraj, F., & Misra, A. (2026). CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188300
Vancouver
Dhanda H, Zaman S, Swain SK, Kushwaha N, Kamal R, Kaur M, et al. CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188300
BibTeX
@article{Dhanda2026,
author = {Dhanda, Himanshu and Zaman, Shamsuz and Swain, Sandeep Kumar and Kushwaha, Neetu and Kamal, Raj and Kaur, Manpreet and Rishi, Bhavika and Tanwar, Pranay and Zaheer, Sufian and Singh, Amitabh and Chaudhry, Sumita and Siraj, Fouzia and Misra, Aroonima},
title = {CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188300}
}
EUVIMED